BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth.
Latest Ratings for BMRN
DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Nov 2021Credit SuisseMaintainsOutperform Nov 2021Morgan StanleyMaintainsEqual-Weight